Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ELVN
Upturn stock ratingUpturn stock rating

Enliven Therapeutics Inc. (ELVN)

Upturn stock ratingUpturn stock rating
$22.05
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/12/2025: ELVN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit -46.8%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/12/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.06B USD
Price to earnings Ratio -
1Y Target Price 37.86
Price to earnings Ratio -
1Y Target Price 37.86
Volume (30-day avg) 238346
Beta -
52 Weeks Range 10.90 - 30.03
Updated Date 02/17/2025
52 Weeks Range 10.90 - 30.03
Updated Date 02/17/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.89

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -21.37%
Return on Equity (TTM) -30.98%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 767517718
Price to Sales(TTM) -
Enterprise Value 767517718
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -6.28
Shares Outstanding 48859200
Shares Floating 26371246
Shares Outstanding 48859200
Shares Floating 26371246
Percent Insiders 6.42
Percent Institutions 102.7

AI Summary

Enliven Therapeutics Inc. (NASDAQ: NVIV) - Comprehensive Overview

Company Profile:

Detailed History and Background:

Enliven Therapeutics Inc. (ENLV) is a clinical-stage company specializing in the development of novel treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. Founded in 2014, the company focuses on its proprietary exosome-based platform, transporting therapeutic molecules across the blood-brain barrier to target specific regions of the brain with precision.

Core Business Areas:

  • Developing exosome-based therapies for neurodegenerative diseases: ENLV's lead product candidates target amyloid beta and tau proteins implicated in Alzheimer's and alpha-synuclein protein associated with Parkinson's.
  • Exosome development and manufacturing platform: ENLV leverages its technology platform to engineer and manufacture customized exosomes for various therapeutic applications.

Leadership Team and Corporate Structure:

  • President and CEO: Dr. Paramjit (Pam) Tanda, Ph.D.
  • Vice President of Business Development: John T. McDonald
  • Vice President of Technology and Manufacturing: Dr. John G. Riordan, Ph.D.
  • Chairman of the Board: Dr. Gary A. Miner

Top Products and Market Share:

  • ENV-101: Exosome-based therapy for Alzheimer's disease, currently in Phase 2a clinical trial.
  • ENV-102: Exosome-based therapy for Parkinson's disease, currently in Phase 1 clinical trial.
  • Exosome development and manufacturing platform: The company currently does not have commercialized exosome products beyond its pipeline.

Market Share:

  • ENV-101: While in clinical trials, ENV-101 does not hold a market share in Alzheimer's disease treatment.
  • ENV-102: Similarly, ENV-102 does not currently hold a market share in Parkinson's disease medication.
  • Exosome platform: The technology platform is not yet commercially available, and its overall market share is difficult to assess.

Product Performance and Market Reception:

Data on product performance and market reception remains limited as both therapeutic candidates are in early-stage clinical trials. Positive results from ongoing trials could significantly impact market perception and future market share potential.

Total Addressable Market:

The global neurodegenerative disease market is substantial, encompassing a wide range of conditions like Alzheimer's, Parkinson's, Huntington's Disease, and Amyotrophic Lateral Sclerosis (ALS). This market is expected to reach a value of $89.43 billion by 2028 with a CAGR of 7.86%.

Financial Performance:

  • Revenue: As a clinical-stage company, ENLV currently generates minimal revenue. In 2022, they reported $549,024 in revenue from research and development collaborations.
  • Net Income: ENLV continues to report net losses due to ongoing research and development activities. In 2022, the net loss was $50.47 million.
  • Profit Margins: The company operates with negative profit margins as it focuses on investing in research and development. In 2022, the operating margin was -855.45%.
  • Earnings per Share (EPS): As a non-profitable company, ENLV has negative EPS. The basic and diluted EPS for 2022 was -1.44.

Year-over-Year Performance:

  • Revenue has shown steady growth over the past years, increasing from $32,000 in 2020 to $549,024 in 2022.
  • Net losses have also increased alongside revenue growth, reflecting continued investment in R&D.
  • Operating margins remain negative, with slight improvement in recent years.

Cash Flow and Balance Sheet:

  • ENLV has minimal cash and cash equivalents with a negative cash flow from operations. The company's ability to continue funding its operations will primarily depend on securing further funding through grants, partnerships, or debt financing.
  • The overall balance sheet shows limited assets and substantial accumulated deficits.

Dividends and Shareholder Returns:

  • ENLV is a non-dividend-paying company as it focuses on reinvesting its capital into research and development.
  • Shareholder returns have been negative over the past years due to the declining stock price.

Growth Trajectory:

  • Historical growth analysis over the past 5-10 years is not particularly relevant as the company was founded in 2014 and is still in the early development stages.
  • Future growth projections rely heavily on the success of the ongoing clinical trials and market reception of its potential therapies.
  • Recent product launches are not yet available, and the impact of current initiatives on long-term growth remains uncertain.

Market Dynamics:

  • The neurodegenerative disease market is characterized by a high unmet need for effective treatments and a growing aging population. However, the market landscape is competitive, with several large pharmaceutical companies and startups vying for the same space.
  • ENLV's competitive advantage lies in its proprietary exosome-based platform technology, offering targeted delivery and potential for higher efficacy. However, the technology is still in development, and competition in the exosome field is growing.

Competitors:

  • Key competitors within the Alzheimer's treatment space include: Biogen (BIIB), Eli Lilly (LLY), Eisai (ESALY), Roche (RHHBY), and Axsome Therapeutics (AXSM).
  • Key competitors within the Parkinson's treatment space include: AbbVie (ABBV), Adamas Pharmaceuticals (ADMS), and Lundbeck (HLUKY).

Market Share Percentages:

  • As ENLV's products are not yet commercially available, calculating market share percentages is not applicable.

Competitive Advantages and Disadvantages:

  • Competitive advantages: Proprietary exosome-based platform technology, potential for increased efficacy and targeted brain delivery.
  • Competitive disadvantages: Early-stage development of therapeutic candidates, limited market presence, unproven technology, competition from established and well-funded players.

Potential Challenges and Opportunities:

  • Key challenges: Regulatory hurdles, clinical trial setbacks, commercialization challenges in a competitive market
  • Potential opportunities: Positive clinical trial outcomes, strategic partnerships, market expansion, and continued development of the exosome-based platform technology.

Recent Acquisitions (last 3 years):

  • ENLV hasn't made any acquisitions in the last 3 years (as of November 2023). However, the company has entered into several collaboration agreements with other entities, including:

  • Collaboration with Emory University: To develop and commercialize exosome-based therapies for neurodegenerative diseases.

  • Collaboration with the Mayo Clinic: To evaluate the potential of ENLV's exosome-based platform for treating Alzheimer's disease.

AI-Based Fundamental Rating:

Rating: 6/10

Justification:

  • Positive aspects: Strong market potential, proprietary technology platform, experienced leadership team
  • Negative aspects: Early-stage of development, limited financial resources, unproven technology, high competition
  • Uncertainty: The success of ENLV's clinical trials and its ability to penetrate the competitive market will significantly impact its future prospects.

Sources and Disclaimers:

Please note: This analysis is based on publicly available information as of November 2023. Information may have changed since.

About Enliven Therapeutics Inc.

Exchange NASDAQ
Headquaters Boulder, CO, United States
IPO Launch date 2020-03-12
Co-Founder, CEO, Secretary & Director Mr. Samuel S. Kintz M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 57
Full time employees 57

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​